MedTrace Logo

Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease

NCT01446614 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-10-05

No results posted yet for this study

Summary

The study is a phase I/II trial designed to establish the safety and efficacy of intravenous administration of autologous bone marrow derived mesenchymal stem cells to patients with Parkinson's disease.

Conditions

Interventions

BIOLOGICAL

bone marrow derived mesenchymal stem cells

Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks

Sponsors & Collaborators

  • Guangzhou General Hospital of Guangzhou Military Command

    lead OTHER

Principal Investigators

  • Yang Xiao, MD · Guangzhou General Hospital of Guangzhou Military Command

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01446614 on ClinicalTrials.gov